LAWRENCE YOUNG: Open Payments
NPI 1568444388 · COMMERCE, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$870 in 46 payments from 17 companies in 2025. Trend: 2023 $844 · 2024 $1,039 · 2025 $870
Food & beverage: $870
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 8 | $195 |
| GlaxoSmithKline, LLC. | 6 | $109 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 6 | $101 |
| PFIZER INC. | 3 | $75 |
| Novo Nordisk Inc | 4 | $70 |
| AstraZeneca Pharmaceuticals LP | 4 | $69 |
| Teva Pharmaceuticals USA, Inc. | 3 | $52 |
| Otsuka America Pharmaceutical, Inc. | 2 | $38 |
| Aimmune Therapeutics, Inc. | 1 | $28 |
| Lundbeck LLC | 1 | $22 |
Products named: VRAYLAR, TRELEGY ELLIPTA, CAPLYTA, ELIQUIS, REXULTI, BREZTRI, AUSTEDO XR, Ozempic.
Industry payments across TX — which companies pay providers there.
